UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~March 2910, 2026

Prelude Therapeutics Incorporated

(Exact Name of Registrant as Specified in its Charter)



Delaware	001-39527		81-1384762
(State or other jurisdiction of incorporation or organization)	(Commission File Number)		(I.R.S. Employer Identification No.)

175 Innovation Boulevard Wilmington, Delaware		19805
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (302) 467-1280

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	PRLD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On March 10, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

OnThe ~~February~~Company 3,has ~~2026~~prepared ~~Prelude~~investor ~~Therapeutics~~presentation ~~Incorporated~~materials (with information about the "Company"), ~~issued~~which ait ~~press~~intends ~~release~~to ~~announcing~~use ~~that~~as ~~the~~part ~~U.S.~~of ~~Food~~investor ~~and~~presentations. ~~Drug~~A ~~Administration~~copy ~~cleared~~of the ~~Company~~investor topresentation ~~proceed~~materials ~~with~~to abe ~~Phase~~used 1by ~~study~~management ~~under~~for ~~its~~presentations ~~Investigational~~is ~~New~~attached ~~Drug~~as ~~Application~~Exhibit ~~for~~99.2 ~~PRT12396,~~to athis ~~mutant-selective~~Current ~~JAK2V617F~~Report ~~inhibitor~~on ~~being~~Form ~~developed~~8-K ~~for~~and ~~the~~is ~~treatment~~incorporated ofherein ~~patients~~by ~~with certain myeloproliferative neoplasms~~reference.

The information in this Current Report on Form 8-K and in ~~Exhibit~~Exhibits 99.1 and 99.2 attached hereto is being furnished, but shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNumber		Description
99.1		Press Release dated ~~February~~March 310, 2026
99.2		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRELUDE THERAPEUTICS INCORPORATED
Date: February 3, 2026	By:	/s/ Bryant Lim
Date: March 10, 2026	By:	/s/ Bryant Lim
		Bryant Lim
		Chief Financial Officer and Chief Legal Officer

Filing Compare · Prelude Therapeutics Inc